SBI 201
Alternative Names: SBI-201Latest Information Update: 30 May 2025
At a glance
- Originator SHIFTBIO
- Class Transcription factors; Vascular disorder therapies
- Mechanism of Action Hypoxia-inducible factor 1 alpha modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Peripheral arterial disorders
Most Recent Events
- 02 Apr 2025 Early research in Peripheral arterial disorders in South Korea (unspecified route), prior to April 2025 (Shiftbio pipeline, April 2025)